On Tuesday, Adaptive Biotechnologies Corp (NASDAQ: ADPT) was -2.06% drop from the session before settling in for the closing price of $7.77. A 52-week range for ADPT has been $2.56 – $9.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.92% over the past five years. When this article was written, the company’s average yearly earnings per share was at 14.70%. With a float of $141.74 million, this company’s outstanding shares have now reached $147.77 million.
Let’s look at the performance matrix of the company that is accounted for 619 employees. In terms of profitability, gross margin is 58.17%, operating margin of -86.43%, and the pretax margin is -89.17%.
Adaptive Biotechnologies Corp (ADPT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adaptive Biotechnologies Corp stocks. The insider ownership of Adaptive Biotechnologies Corp is 4.61%, while institutional ownership is 92.21%. The most recent insider transaction that took place on Mar 24 ’25, was worth 15,282. In this transaction Chief Scientific Officer of this company sold 1,698 shares at a rate of $9.00, taking the stock ownership to the 1,279,524 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 1,698 for $8.66, making the entire transaction worth $14,705.
Adaptive Biotechnologies Corp (ADPT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.67% during the next five years compared to -1.51% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
You can see what Adaptive Biotechnologies Corp (ADPT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.08, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its 5-day average volume 1.59 million, a negative change from its year-to-date volume of 1.91 million. As of the previous 9 days, the stock’s Stochastic %D was 74.16%. Additionally, its Average True Range was 0.62.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 56.32%, which indicates a significant increase from 45.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.51% in the past 14 days, which was lower than the 75.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.80, while its 200-day Moving Average is $6.08. Nevertheless, the first resistance level for the watch stands at $7.79 in the near term. At $7.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.13. If the price goes on to break the first support level at $7.44, it is likely to go to the next support level at $7.28. The third support level lies at $7.10 if the price breaches the second support level.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
There are 148,582K outstanding shares of the company, which has a market capitalization of 1.13 billion. As of now, sales total 178,960 K while income totals -159,490 K. Its latest quarter income was 47,460 K while its last quarter net income were -33,690 K.
